References (continued)

40. Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of us oncology research trial 9735. J Clin Oncol. 2009;27(8):1177–1183. doi:10.1200/JCO.2008.18.4028

41. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–2313. doi:10.1056/NEJMoa043681


Continue Reading

42. Jones SE, Collea R, Paul D, et al. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, Phase 2 study. Lancet Oncol. 2013;14(11):1121–1128. doi:10.1016/S1470-2045(13)70384-X

43. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513–2531. doi:10.2165/00003495-200565170-00007

44. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17(5):1413–1424. doi:10.1200/JCO.1999.17.5.1413

45. Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19–24.

46. Mavroudis D, Alexopoulos A, Malamos N, et al. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter Phase II trial. Oncology. 2003;64(3):207–212. doi:10.1159/000069306

47. Perez EA, Suman VJ, Fitch TR, et al. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Oncology. 2005;69(2):117–121. doi:10.1159/000087813

48. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol. 2011;29(2):149–156. doi:10.1200/JCO.2010.28.6450

49. Riva A, Reese D, Toppmeyer D, et al. Results of Two open-label, multicenter phase ii studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. JNCI. 2004;96(10):759–769. doi:10.1093/jnci/djh133

50. Ashraf QM, Sajad QR, Khan MA, et al. Efficacy and safety of a novel nanosomal docetaxel lipid suspension as an anticancer agent – a retrospective study. J Cancer Oncol. 2018;2(4):000132.

Source: Breast Cancer: Targets and Therapy.
Originally published May 22, 2020.

READ FULL ARTICLE Curated publisher From Dovepress